|
For the first time, researchers have found that brain stem cells
are "immune privileged," meaning that they are not rejected
by a transplant recipient's immune system.
These results,
published in the journal Stem Cells, suggest that using central
nervous system stem cells in transplants for diseases of the eye
(which is part of the brain), brain, and spinal cord, may eliminate
the need for tissue typing before, and immunosuppressive drugs
after, transplantation.
Ultimately
these findings may improve the success of retinal transplantation
to regenerate vision for millions with macular degeneration, retinitis
pigmentosa and diabetic retinopathy, and brain transplants to
restore functioning for patients with disorders such as Parkinson's
disease.
"These
findings are very exciting," said Michael Young, an assistant
professor at Harvard Medical School. "Though we suspected
brain stem cells might be protected in this way, this is the first
documented evidence."
In their study,
the researchers chose a part of the body that always rejects transplanted
tissue without immunosuppressant drugs and without close tissue
typing the kidney capsule, the pouch in which the kidney
is located.
They took
brain stem cells from green mice (mice in which the gene for green
protein found in jellyfish has been inserted) and placed them
under the kidney capsule in other normal non-green mice.
After 4 weeks,
the team examined the mice and found that the stem cells had not
been rejected in any of the mice, and, in fact, had grown into
neural tissue.
"Now
we know that at least brain stem cells are immune privileged and
can be used without the same worry about tissue matching or immunosuppression
that is true for other types of tissue," Young said.
"Understanding
the immune properties of these stem cells could have an enormous
effect on how we perform brain or retinal transplantations in
the future. Stem cells already have the advantage of being able
to transform or differentiate into various types of cells and
can be reproduced endlessly outside the body," he added.
Other
Sources: Schepens
Eye Research Institute
|